Developer docs
API playgroundTry for free, no card

Search company profiles

Dermapharm

Full company profile

uuid000br2b

Namestring
Dermapharm
Legal namestring
Dermapharm Holding SE
Websiteurl
dermapharm.de
Company typeenum
Public
Founded yearint
1991
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGrünwald, Germany
HQ citystring
Grünwald
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded pharmaceuticals, dermatological products, cannabinoid medicines, OTC medications, parallel import pharmaceuticals
Industry4 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAE
Topical & Dermatology Generics
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Branded Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Branded Pharmaceuticals (Markenarzneimittel)
TypeOne Time License
Description

Core revenue driver; includes branded generics and prescription/OTC pharmaceutical products developed and manufactured in-house, distributed via a pharmaceutical-trained external sales force. This segment is the primary growth engine, posting 11.7% revenue growth in Q1 2026.

ir.dermapharm.de
2Other Healthcare Products
TypeOne Time License
Description

Encompasses herbal medicines (e.g., Arkopharma), food supplements, topical dermatological products, and other health-related products. Includes Montavit (Austria), Arkopharma (France), and other brand acquisitions.

ir.dermapharm.de
3Parallel Import Business
TypeTransaction Fee
Description

Parallel importation of pharmaceutical products, which has been undergoing scheduled wind-down/portfolio optimization, leading to planned revenue declines in this segment.

ir.dermapharm.de
4Contract Manufacturing / BioNTech Cooperation
TypeProfessional Services
Description

Contract manufacturing operations, notably the COVID-19 vaccine production cooperation with BioNTech SE, which contributed high double-digit million euro revenue in 2021. Now substantially wound down following pandemic phase.

ir.dermapharm.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Dekristolvit
Description

Vitamin D supplement product

ir.dermapharm.de
+5 more records
Core offering1 text field

Dermapharm is a growth-oriented manufacturer of branded pharmaceuticals and other healthcare products operating an integrated in-house development, production, and distribution model. It sells branded generics, prescription and OTC medications across dermatology, allergies, pain, neurology, oncology (cannabinoid/dronabinol), and cardiovascular health, plus herbal medicines, food supplements, and parallel-imported drugs, distributed through a pharmaceutical-trained external sales force to pharmacies and healthcare professionals across Germany and wider Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Q1 2026 revenue of €305.8 million, up 1.1% YoY
+4 more records
Product overview1 text field

Dermapharm is a growth-oriented manufacturer of branded pharmaceuticals and other healthcare products with an integrated business model encompassing in-house development, production, and distribution through a pharmaceutical-trained sales force. The company operates across three main segments: Branded Pharmaceuticals (prescription and OTC medications including Dekristolvit®, herpotherm® neo, Keltican® forte, Minoxicutan®, Ketozolin®, and Tromcardin® complex), Other Healthcare Products (herbal medicines and supplements), and Parallel Import Business. The company holds over 1,400 drug approvals and maintains a pipeline of more than 50 ongoing development projects, with production primarily based in Germany (main site in Brehna near Leipzig) and operations across Europe and the USA.

Product and service11 records
1Dekristolvit
CategoryOTC Pharmaceutical
Description

Vitamin D supplement offering individualized dosing for different life stages and needs, sold as an OTC product through pharmacies in Germany.

2herpotherm neo
CategoryMedical Device
Description

Heat-based medical device (herpes warming pen) for treating lip herpes, distributed through German pharmacies.

3Keltican forte
CategoryOTC Pharmaceutical
Description

Branded nerve-regeneration supplement supporting the body's own regeneration of peripheral nerves, sold through pharmacies.

4Minoxicutan
CategoryOTC Pharmaceutical
Description

Minoxidil-based affordable alternative hair growth treatment for hair loss, sold OTC through pharmacies.

5Ketozolin
CategoryOTC Pharmaceutical
Description

2% shampoo for treating dandruff and itching on scalp and body, sold OTC through pharmacies.

6Tromcardin complex
CategoryOTC Pharmaceutical
Description

Established electrolyte combination with vitamin B1 for healthy heart function, sold as a branded product through pharmacies.

7Dronabinol Products
CategoryPrescription Pharmaceutical
Description

Cannabinoid-based pharmaceutical products used in pain, oncology, and neurology treatments; Dermapharm holds market leadership in dronabinol in Germany/Austria via the C³ Group acquired in 2022.

8Branded Pharmaceuticals Segment
CategoryBranded Pharmaceuticals
Description

Core business segment encompassing prescription and OTC branded medications across dermatology, allergies, neurology, cardiology, and pain management, distributed via Dermapharm's pharmaceutical-trained external sales force.

9Other Healthcare Products
CategoryHerbal Medicines and Supplements
Description

Business segment covering herbal medicines, food supplements, and other health-related products, including the Arkopharma and Montavit brands.

10Parallel Import Pharmaceuticals (Axicorp)
CategoryParallel Import Pharmaceuticals
Description

Parallel importation of branded pharmaceutical products from other EU markets into Germany at different price points, operated via subsidiary Axicorp; undergoing scheduled wind-down as part of portfolio optimization.

11Allergopharma Allergy Immunotherapy Products
CategoryAllergy Therapeutics
Description

Allergen immunotherapy and vaccine products marketed through Dermapharm's wholly owned subsidiary Allergopharma GmbH & Co. KG, acquired in 2020.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-15
Description

Dermapharm acquired the C³ Cannabinoid Compound Company GmbH (C³ Group) from Canopy Growth Germany GmbH for an upfront payment of EUR 80 million plus possible additional earnout payments based on future milestones. The acquisition was completed on January 31, 2022, and includes subsidiaries in Germany and Austria. It strengthens Dermapharm's position as a market leader in dronabinol, a cannabinoid used in pain, oncology, and neurology treatments.

2BioNTech SE
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-10
Description

Dermapharm signed a cooperation and delivery agreement with BioNTech SE for the production of a COVID-19 vaccine. The cooperation was expected to contribute high double-digit million euro in revenue in 2021. Dermapharm expanded capacity at subsidiary Allergopharma for vaccine manufacturing, and Federal Minister of Health Jens Spahn opened the facility in April 2021. The pandemic-phase vaccine cooperation has since wound down substantially.

ir.dermapharm.de
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Almirall is a Barcelona-based specialty pharmaceutical company focused on dermatology, offering branded prescription and OTC products across skin conditions. Both companies share a dermatology-focused specialty pharma identity with European distribution footprints and similar therapeutic area coverage.

TypeRegional player
Description

Klosterfrau is a German OTC and herbal medicine manufacturer with established pharmacy distribution. It overlaps with Dermapharm's German OTC and Arkopharma herbal medicine portfolio, particularly in branded consumer health products sold through German pharmacy channels.

TypeDirect peer
Description

Pierre Fabre is a French pharmaceutical and dermo-cosmetics company with strong dermatology, oncology, and consumer healthcare portfolios. Its integrated pharma + dermocosmetics model across French and broader European markets is closely comparable to Dermapharm's branded specialty and OTC dermatology business.

TypeDirect peer
Description

Galderma is a Switzerland-based pure-play dermatology company specializing in prescription, OTC, and aesthetic skin products. As one of the largest dermatology-focused pharmaceutical companies globally, Galderma represents a direct competitive peer in Dermapharm's core therapeutic category.

TypeBroad incumbent
Description

Merck KGaA is a German multinational science and technology company with a healthcare division covering specialty pharmaceuticals and consumer health. As a major German pharma incumbent with branded specialty products and pharmacy distribution, it provides a broader market benchmark for Dermapharm's domestic positioning.

6Sandoz Group AG
TypeBroad incumbent
Description

Sandoz is a recently independent global leader in generic and biosimilar medicines, spun out from Novartis. Its European generics footprint and growing specialty focus make it a relevant comparable for Dermapharm's branded generics strategy.

TypeBroad incumbent
Description

Sanofi is a French multinational pharmaceutical company with consumer healthcare operations including branded OTC products. Its European pharmacy channel presence and consumer health division provide a broader benchmark against Dermapharm's branded specialty and OTC portfolio.

TypeBroad incumbent
Description

Bayer is a German multinational pharmaceutical and consumer health company with substantial OTC and consumer care operations. Its Consumer Health division competes with Dermapharm's OTC and dermatology portfolio through pharmacy retail channels across Europe.

TypeBroad incumbent
Description

Teva is a global generic and specialty pharmaceutical company with broad OTC and dermatology offerings. As the world's largest generic drug manufacturer, Teva represents a broader incumbent peer against Dermapharm's branded generics and specialty pharma business.

TypeDirect peer
Description

Stada is a German specialty and generic pharmaceuticals company headquartered in Bad Vilbel. Both companies operate integrated pharmaceutical manufacturing models with branded generics, OTC products, and specialty pharma portfolios distributed primarily through German pharmacy channels — making Stada Dermapharm's closest direct comparable in scale and business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dermapharm

Branded Pharmaceuticalsdermapharm.de

Dermapharm firmographics

Firmographics
Name
Dermapharm
Legal name
Dermapharm Holding SE
Website
https://dermapharm.de
Company type
Public
Founded year
1991
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Dermapharm industry classification

Industry
Product category
Branded Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAE
Topical & Dermatology Generics
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Branded pharmaceuticals
  • Dermatological products
  • Cannabinoid medicines
  • OTC medications
  • Parallel import pharmaceuticals

Where Dermapharm is headquartered

Location

Headquarters

HQ city
Grünwald
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

Dermapharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Branded Pharmaceuticals (Markenarzneimittel): Core revenue driver; includes branded generics and prescription/OTC pharmaceutical products developed and manufactured in-house, distributed via a pharmaceutical-trained external sales force. This segment is the primary growth engine, posting 11.7% revenue growth in Q1 2026.
  2. Other Healthcare Products: Encompasses herbal medicines (e.g., Arkopharma), food supplements, topical dermatological products, and other health-related products. Includes Montavit (Austria), Arkopharma (France), and other brand acquisitions.
  3. Parallel Import Business: Parallel importation of pharmaceutical products, which has been undergoing scheduled wind-down/portfolio optimization, leading to planned revenue declines in this segment.
  4. Contract Manufacturing / BioNTech Cooperation: Contract manufacturing operations, notably the COVID-19 vaccine production cooperation with BioNTech SE, which contributed high double-digit million euro revenue in 2021. Now substantially wound down following pandemic phase.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Dermapharm product offering

Product offering

Core offering

Dermapharm is a growth-oriented manufacturer of branded pharmaceuticals and other healthcare products operating an integrated in-house development, production, and distribution model. It sells branded generics, prescription and OTC medications across dermatology, allergies, pain, neurology, oncology (cannabinoid/dronabinol), and cardiovascular health, plus herbal medicines, food supplements, and parallel-imported drugs, distributed through a pharmaceutical-trained external sales force to pharmacies and healthcare professionals across Germany and wider Europe.

Product overview

Dermapharm is a growth-oriented manufacturer of branded pharmaceuticals and other healthcare products with an integrated business model encompassing in-house development, production, and distribution through a pharmaceutical-trained sales force. The company operates across three main segments: Branded Pharmaceuticals (prescription and OTC medications including Dekristolvit®, herpotherm® neo, Keltican® forte, Minoxicutan®, Ketozolin®, and Tromcardin® complex), Other Healthcare Products (herbal medicines and supplements), and Parallel Import Business. The company holds over 1,400 drug approvals and maintains a pipeline of more than 50 ongoing development projects, with production primarily based in Germany (main site in Brehna near Leipzig) and operations across Europe and the USA.

Differentiator

Problem solved

Functional benefit

Brands

  • Dekristolvit: Vitamin D supplement product
  • herpotherm
  • Keltican
  • Minoxicutan
  • Ketozolin
  • Tromcardin

Products and services

  • Dekristolvit Vitamin D supplement offering individualized dosing for different life stages and needs, sold as an OTC product through pharmacies in Germany.
  • herpotherm neo Heat-based medical device (herpes warming pen) for treating lip herpes, distributed through German pharmacies.
  • Keltican forte Branded nerve-regeneration supplement supporting the body's own regeneration of peripheral nerves, sold through pharmacies.
  • Minoxicutan Minoxidil-based affordable alternative hair growth treatment for hair loss, sold OTC through pharmacies.
  • Ketozolin 2% shampoo for treating dandruff and itching on scalp and body, sold OTC through pharmacies.
  • Tromcardin complex Established electrolyte combination with vitamin B1 for healthy heart function, sold as a branded product through pharmacies.
  • Dronabinol Products Cannabinoid-based pharmaceutical products used in pain, oncology, and neurology treatments; Dermapharm holds market leadership in dronabinol in Germany/Austria via the C³ Group acquired in 2022.
  • Branded Pharmaceuticals Segment Core business segment encompassing prescription and OTC branded medications across dermatology, allergies, neurology, cardiology, and pain management, distributed via Dermapharm's pharmaceutical-trained external sales force.
  • Other Healthcare Products Business segment covering herbal medicines, food supplements, and other health-related products, including the Arkopharma and Montavit brands.
  • Parallel Import Pharmaceuticals (Axicorp) Parallel importation of branded pharmaceutical products from other EU markets into Germany at different price points, operated via subsidiary Axicorp; undergoing scheduled wind-down as part of portfolio optimization.
  • Allergopharma Allergy Immunotherapy Products Allergen immunotherapy and vaccine products marketed through Dermapharm's wholly owned subsidiary Allergopharma GmbH & Co. KG, acquired in 2020.

Quantifiable outcome

  • Q1 2026 revenue of €305.8 million, up 1.1% YoY
  • +4 more outcomes

Companies that use Dermapharm

Customer profile

Segments2 records

Ideal customer profiles2 records

Dermapharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dermapharm partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Canopy Growth Germany GmbHcoreStrategic or Co-development Partner · 15 December 2021Dermapharm acquired the C³ Cannabinoid Compound Company GmbH (C³ Group) from Canopy Growth Germany GmbH for an upfront payment of EUR 80 million plus possible additional earnout payments based on future milestones. The acquisition was completed on January 31, 2022, and includes subsidiaries in Germany and Austria. It strengthens Dermapharm's position as a market leader in dronabinol, a cannabinoid used in pain, oncology, and neurology treatments.
  • BioNTech SEcoreStrategic or Co-development Partner · 10 September 2020Dermapharm signed a cooperation and delivery agreement with BioNTech SE for the production of a COVID-19 vaccine. The cooperation was expected to contribute high double-digit million euro in revenue in 2021. Dermapharm expanded capacity at subsidiary Allergopharma for vaccine manufacturing, and Federal Minister of Health Jens Spahn opened the facility in April 2021. The pandemic-phase vaccine cooperation has since wound down substantially.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Dermapharm competitors and assessment

Company assessment

Direct peers

  • Almirall S.A. Almirall is a Barcelona-based specialty pharmaceutical company focused on dermatology, offering branded prescription and OTC products across skin conditions. Both companies share a dermatology-focused specialty pharma identity with European distribution footprints and similar therapeutic area coverage.
  • Pierre Fabre Group: Pierre Fabre is a French pharmaceutical and dermo-cosmetics company with strong dermatology, oncology, and consumer healthcare portfolios. Its integrated pharma + dermocosmetics model across French and broader European markets is closely comparable to Dermapharm's branded specialty and OTC dermatology business.
  • Galderma S.A. Galderma is a Switzerland-based pure-play dermatology company specializing in prescription, OTC, and aesthetic skin products. As one of the largest dermatology-focused pharmaceutical companies globally, Galderma represents a direct competitive peer in Dermapharm's core therapeutic category.
  • Stada Arzneimittel AG: Stada is a German specialty and generic pharmaceuticals company headquartered in Bad Vilbel. Both companies operate integrated pharmaceutical manufacturing models with branded generics, OTC products, and specialty pharma portfolios distributed primarily through German pharmacy channels — making Stada Dermapharm's closest direct comparable in scale and business model.

Regional players

  • Klosterfrau München GmbH: Klosterfrau is a German OTC and herbal medicine manufacturer with established pharmacy distribution. It overlaps with Dermapharm's German OTC and Arkopharma herbal medicine portfolio, particularly in branded consumer health products sold through German pharmacy channels.

Broad incumbents

  • Merck KGaA: Merck KGaA is a German multinational science and technology company with a healthcare division covering specialty pharmaceuticals and consumer health. As a major German pharma incumbent with branded specialty products and pharmacy distribution, it provides a broader market benchmark for Dermapharm's domestic positioning.
  • Sandoz Group AG: Sandoz is a recently independent global leader in generic and biosimilar medicines, spun out from Novartis. Its European generics footprint and growing specialty focus make it a relevant comparable for Dermapharm's branded generics strategy.
  • Sanofi S.A. Sanofi is a French multinational pharmaceutical company with consumer healthcare operations including branded OTC products. Its European pharmacy channel presence and consumer health division provide a broader benchmark against Dermapharm's branded specialty and OTC portfolio.
  • Bayer AG: Bayer is a German multinational pharmaceutical and consumer health company with substantial OTC and consumer care operations. Its Consumer Health division competes with Dermapharm's OTC and dermatology portfolio through pharmacy retail channels across Europe.
  • Teva Pharmaceutical Industries Ltd. Teva is a global generic and specialty pharmaceutical company with broad OTC and dermatology offerings. As the world's largest generic drug manufacturer, Teva represents a broader incumbent peer against Dermapharm's branded generics and specialty pharma business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Dermapharm social profiles

Digital presence

Dermapharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dermapharm leadership team

Management profile

Number of profiles

Profiles4 records

Dermapharm subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Dermapharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dermapharm M&A and investment

M&A and investment

M&A5 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermapharm

What does Dermapharm do?

Dermapharm is a growth-oriented manufacturer of branded pharmaceuticals and other healthcare products operating an integrated in-house development, production, and distribution model. It sells branded generics, prescription and OTC medications across dermatology, allergies, pain, neurology, oncology (cannabinoid/dronabinol), and cardiovascular health, plus herbal medicines, food supplements, and parallel-imported drugs, distributed through a pharmaceutical-trained external sales force to pharmacies and healthcare professionals across Germany and wider Europe.

Is Dermapharm a public or private company?

Dermapharm is a public company. It is classified as public and is currently operating.

When was Dermapharm founded?

Dermapharm was founded in 1991. It employs 11 to 50 people.

Where is Dermapharm based?

Dermapharm is headquartered in Grünwald, Germany, in the Europe region.

How does Dermapharm make money?

Four revenue lines are on record. Branded Pharmaceuticals (Markenarzneimittel) is the primary driver. The others are other Healthcare Products, parallel Import Business and contract Manufacturing / BioNTech Cooperation.

Who are Dermapharm's main competitors?

Direct peers on record are Almirall S.A., Pierre Fabre Group, Galderma S.A. and Stada Arzneimittel AG. Klosterfrau München GmbH is listed as a regional player. Broad incumbents are Merck KGaA, Sandoz Group AG, Sanofi S.A., Bayer AG and Teva Pharmaceutical Industries Ltd..

Does Dermapharm have an API?

No public API is recorded for Dermapharm.

What industry is Dermapharm in?

Dermapharm's product category is Branded Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingDermapharm Publishes Q3 2026 Results Call TranscriptDermapharm reaffirmed its 2026 guidance at its November 12 Q3 results call, expecting branded products to offset weakness elsewhere. Nine-month revenue rose 1.7% to 884 million, and operating cash flow increased 10% to about 149 million. Management cited likely timing effects for a third-quarter branded pharmaceuticals decline.Simply Wall StDermapharm Holding (XTRA:DMP) The Latest Update Raises A Bigger QuestionDermapharm Holding reported nine-month results to September 30, 2026, showing higher sales, lower net profit, and improved EPS from continuing operations. The stock trades at a P/E of 13.4x, below its fair-value benchmark of 16.8x, while a DCF model values shares at €99.14 versus the current €35.25.TradingViewDermapharm Q3 2026 Earnings Call Is LiveDermapharm's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.InvestegateEQS-News: Strong existing business in the "Branded pharmaceuticals" segment drives positive performanceDermapharm Holding SE reported consolidated revenue of EUR 884.4 million for the first nine months of 2026, up 1.7% year on year. Adjusted EBITDA rose 5.1% to EUR 248.1 million, with the branded pharmaceuticals segment driving growth. The company confirmed its 2026 financial guidance.Investing.comDermapharm reports third quarter results, confirms guidanceDermapharm Holding SE reported Q3 2026 sales of €294m, flat year-over-year and 1% below consensus, with adjusted EBITDA of €85m, 4% above estimates. The company confirmed its full-year guidance, implying Q4 sales growth of 1% to reach the low end of the target.TradingViewDMP: Branded growth lifted 9M revenue and adjusted EBITDA; FY 2026 guidance was reaffirmedDermapharm Holding reported branded growth that lifted revenue to €884.4m and adjusted EBITDA to €248.1m, up 1.7% and 5.1% respectively. The company reaffirmed its FY 2026 revenue guidance of €1,182–1,218m and adjusted EBITDA guidance of €331–341m.TradingViewDMP: Branded Pharmaceuticals growth supports confirmed FY guidance despite earnings headwindsDermapharm Holding SE confirmed its FY2026 revenue and adjusted EBITDA guidance, citing growth in Branded Pharmaceuticals. Revenue, adjusted EBITDA, and operating cash flow all increased, though higher depreciation and one-off items weighed on earnings.InvestegateEQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statementsDermapharm Holding SE announced it will disclose its Q3 quarterly financial report in German and English on November 12, 2026. The announcement was made via the EQS Distribution Services news service.FinanzNachrichten.deJEFFERIES stuft Dermapharm auf 'Hold'Jefferies kept Dermapharm on 'Hold' with a €44 price target after meeting CFO Christof Dreibholz. The analyst sees Allergopharma gaining market share in a structurally attractive market, with internationalization potential and Arkopharma recovery.FinanzNachrichten.deBERENBERG stuft Dermapharm auf 'Buy'Berenberg analyst Christian Ehmann maintained a "Buy" rating on Dermapharm with a price target of 60 euros, citing the branded pharmaceutical business as a driver of rising profitability. He also noted that portfolio optimization in the parallel import segment is yielding results. No valuation or financial figures were disclosed.